Quarterly ResultApr 30, 2026, 07:31 AM
BRNS Q1 Net Loss $(5.5)M; Clywedog Merger Progressing; New CFO
AI Summary
Barinthus Bio reported a Q1 2026 net loss of $(5.5) million, a significant improvement from $(19.6) million in Q1 2025. The company announced that its proposed combination with Clywedog Therapeutics Inc. is progressing towards a mid-2026 closing, aiming to create a differentiated company focused on metabolic and autoimmune diseases with an estimated cash runway through 2027. Additionally, Doug Swirsky was appointed CFO, effective May 1, 2026, and Phase 1 AVALON trial data for VTP-1000 in celiac disease is expected in H2 2026.
Key Highlights
- Proposed merger with Clywedog Therapeutics Inc. progressing towards mid-2026 closing; combined company to trade as "CLYD".
- Combined company's estimated cash runway expected to extend through 2027.
- Q1 2026 net loss attributable to shareholders was $(5.5) million, or $(0.14) per share.
- Cash, cash equivalents, and restricted cash were $67.2 million as of March 31, 2026.
- Research and development expenses decreased to $3.6 million in Q1 2026 from $8.3 million in Q1 2025.
- General and administrative expenses decreased to $2.5 million in Q1 2026 from $12.6 million in Q1 2025.
- Multiple ascending dose data from Phase 1 AVALON trial of VTP-1000 expected in H2 2026.
- Doug Swirsky appointed Chief Financial Officer, effective May 1, 2026.